Jennifer Hensley, MD
Dermatology · Elgin, ILNPI 1467624528
Payments from drug & device makers
Across 24 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$197
- Almirall LLC$177
- Boehringer Ingelheim$39
- Mayne Pharma Commercial LLC$26
- Medimetriks Pharmaceuticals, Inc.$25
- AbbVie$24
- plus $121 from 8 others
What the payments were for
- Food & beverage$51885%
- Education$9215%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $197 |
| Almirall LLC | 4 | $177 |
| Boehringer Ingelheim | 1 | $39 |
| Mayne Pharma Commercial LLC | 1 | $26 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $25 |
| AbbVie | 1 | $24 |
| Promius Pharma LLC | 1 | $21 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $20 |
| Taro Pharmaceuticals USA, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $13 |
| Galderma Laboratories, L.p. | 1 | $11 |
| Journey Medical Corporation | 1 | $5 |
How this compares
$610 in reported general payments places this provider in the 25th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $272,274 |
| Humira(Cf) PenAdalimumab | 25 | $173,689 |
| Dupixent PenDupilumab | 18 | $103,484 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $87,129 |
| OtezlaApremilast | 12 | $57,691 |
| Clobetasol Propionate | 136 | $7,045 |
| Ketoconazole | 182 | $3,215 |
| Calcipotriene | 13 | $3,059 |
| Desonide | 23 | $2,720 |
| Fluorouracil | 24 | $1,723 |
| Doxycycline Hyclate | 44 | $1,486 |
| Triamcinolone Acetonide | 141 | $1,170 |
| Mycophenolate Mofetil | 14 | $1,145 |
| Clindamycin Phosphate | 35 | $1,057 |
| Fluocinonide | 19 | $904 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Elgin
- Michael BukhaloRolling Meadows$6.8M
- Stephanie MehlisSkokie$6.4M
- Ahmad AminNaperville$4.6M
- George LewittNorthbrook$4M
- Raj ChovatiyaChicago$3.7M
- Peter LioChicago$2.5M
- Paul GetzWest Dundee$2.4M
- Kyle AmberBerwyn$2.3M
- Elizabeth KiracofeChicago$1.6M
- Lana SchmidtEffingham$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.